OBR Daily Commentary

forumImage

Major Milestone Achieved in CytRx’s Phase 2b Global Clinical Trial with Tamibarotene as a First-Line Treatment for Non-Small-Cell Lung Cancer

(4-traders) June 25, 2012 - CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the recommendation by the Data Safety Monitoring Board (DSMB) to continue with the global Phase 2b clinical trial with tamibarotene in combination with chemotherapeutical agents as a first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC).

Read Article arrow

H. Jack West, MD (Posted: June 25, 2012)

quotesThis is a press release highlighting that the trial hasn't been stopped because of prohibitive toxicity from the treatment. I'm not sure that we should have such a low bar for celebration that "we're not horribly dangerous" should be reason to hear champagne corks popping. quotes

Add Comment 1 Comment
forumImage

NovaRx Completes Enrollment in Lucanix Pivitol Phase III Therapeutic Vaccine Trial for Post Frontline Maintenace Therapy in Non Small Cell Lung Cancer

(BizJournals) June 20, 2012 - First interim analysis for NSCLC trial in third quarter 2012 - NovaRx Corporation announced that it has recently completed the planned enrollment in its Phase III clinical trial of Lucanix® (belagenpumatucel-L). Lucanix is an investigational whole tumor cell vaccine for the treatment of non-small cell lung cancer.

Read Article arrow

H. Jack West, MD (Posted: June 20, 2012)

quotesWe'll need to see what the results demonstrate, but this is certainly among the most interesting maintenance therapy trials, as well as immunotherapy trials, in lung cancer. Even with the availability of maintenance chemotherapy or erlotinib, there would be a great appeal for an immunotherapy-based treatment with minimal adverse effects. As immunotherapies for cancer gain momentum, a positive trial for belagenpumatucel-L (Lucanix) would be another valuable landmark, and one that could be tested in other lung cancer settings as well. quotes

Add Comment 1 Comment
forumImage

New Therapy Extends Life for Prostate Cancer Patients

(SNM) June 11, 2012 - Prostate cancer patients with advanced tumors that have spread to bone have a poor chance of surviving. Patients with the disease may now live longer with a new line of radioisotope therapy, say researchers at the Society of Nuclear Medicine’s 2012 Annual Meeting.

Read Article arrow

H. Jack West, MD (Posted: June 12, 2012)

quotesRadium-223 is an alpha emitting radioisotope that both significantly improves overall survival (by 3 months) compared with placebo but also reduces skeletal related events in men with metastatic prostate cancer. It also doesn't cause serious problems with irreversible myelosuppression. Once FDA-approved, hopefully later this year, it will be a terrific addition to our armamentarium for prostate cancer, where so many patients have extensive bone metastases and where well-tolerated approaches that significantly prolong survival are in short supply. quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...